Revvity (RVTY)
Healthcare · NYSE · US
Price as at 1 Oct 2026, 00:50 UTC. Quotes are delayed.
Fundamentals
Valuation and ratings
Revvity trades at $152.89, which is 58% above the $64.34 our fair value estimate puts on the business. On that measure it screens as expensive, which is not the same as saying it will fall.
Our moat model scores it 52 out of 100, which is a moat, but not a deep one. A moat is a structural reason competitors cannot take the profits away, and it matters more to a long holding period than any single quarter's numbers do.
It changes hands at 54.0 times earnings. Be careful reading that in isolation: for a cyclical business a low P/E arrives at the top of the cycle, when profits are peaking and about to fall, which is exactly when the shares look cheapest and are not.
RVTY dividend history
Dividends per share by year
| Year | Total per share | Payments |
|---|---|---|
| 2026 (year to date) | $0.070 | 1 |
| 2025 | $0.070 | 1 |
| 2024 | $0.280 | 4 |
| 2023 | $0.280 | 4 |
| 2022 | $0.280 | 4 |
| 2021 | $0.280 | 4 |
| 2020 | $0.280 | 4 |
| 2019 | $0.280 | 4 |
| 2018 | $0.280 | 4 |
| 2017 | $0.280 | 4 |
| 2016 | $0.280 | 4 |
Split-adjusted amounts in the listing currency, grouped by the calendar year of the ex-dividend date, from the filed record. Growth and streak figures compare complete years only.
RVTY earnings and analyst estimates
Recommendation mix, 17 published ratings
Estimates are the published analyst consensus and move often. An earnings date is scheduled, not certain, and a share tends to reprice most violently on the day itself.
About Revvity
Revvity, Inc. provides health sciences solutions, technologies, and services. The company offers instruments, reagents, software, subscriptions, detection and imaging technologies, extended warranties, training and services; and instruments, reagents, assay platforms and software products for early detection of common and rare conditions, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. The company also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, chemagic, Chitas, CNGnome, DELFIA, DELFIA Xpress, EONIS, EUROArray , EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPattern, Evolution Evoya, GSP, Haoyuan, IDS Immunodiagnosticsystems, IDS-i10, IDS-i10T, IDS-i20, IDS-iSYS, iLab, iQ, LifeCycle, LimsLink, Migele, NeoBase, NeoLSD, NEXTFLEX, Panthera Puncher, PreNAT II, Prime, RONIA, SimplicityChrom, Specimen Gate, Superflex, Symbio, T-SPOT, Vanadis, ViaCord, VICTOR2, and WholePanel brand names, as well as under the Accell, AlphaLISA, AlphaPlex, AlphaScreen, Alpha SureFire, AssayMate, BIOCHIPs, BioLegend, Bioo Scientific, BioQule, Brilliant Violet, Ce3D, CellCarrier, Cellaca, Celigo, Cellometer, cell::explorer, Cell-Vive, Chalice, ChemDraw, CHOSOURCE, Dharmacon, and DharmaFECT brand names. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.
Company profile, industry and headcount are as reported by our data provider and can lag a company's own filings by a reporting period. The annual report is the authority.
RVTY passes 1 of our 30 screens today
Each screen prints the exact criteria it used, and the circumstances in which it is wrong.
Super investor ownership
10 of the funds we track reported a position in their latest SEC 13F filing. Largest first:
- Ken Griffin, CITADEL ADVISORS LLC$162.14M · 0.0% of book
- Diamond Hill, Diamond Hill Capital Management, LLC (Investment Advisor)$42.87M · 0.3% of book
- Cliff Asness, AQR CAPITAL MANAGEMENT LLC$13.96M · 0.0% of book
- Marshall Wace, MARSHALL WACE, LLP$12.63M · 0.0% of book
- Israel Englander, MILLENNIUM MANAGEMENT LLC$8.37M · 0.0% of book
A word of warning on reading these figures: a 13F reports the market value of a holding, so a fund that traded nothing at all still appears to have sold when the price fell. We found 102 companies where the standard reading gives the opposite answer. Only the share count is honest.
Politician trades in RVTY
We hold 9 disclosed trades in RVTY by members of Congress and executive-branch officials. The latest 5:
- Gilbert Cisneros · HouseBuy · $15,001 - $50,000 · traded 4 May 2026 · disclosed 8 Jun 2026
- Gilbert Cisneros · HouseBuy · $1,001 - $15,000 · traded 1 May 2026 · disclosed 8 May 2026
- Donald J Trump · Executive branchSell · $15,001 - $50,000 · traded 27 Apr 2026 · disclosed 1 Jul 2026
- Gilbert Cisneros · HouseBuy · $1,001 - $15,000 · traded 12 Sept 2025 · disclosed 10 Oct 2025
- Gilbert Cisneros · HouseBuy · $1,001 - $15,000 · traded 13 Aug 2025 · disclosed 12 Sept 2025
A disclosure reports a value band, not an amount, and is due up to 45 days after the trade; some arrive later. Every filer we track, each with their own page, is on the Congress trading tracker.
RVTY peers
The largest companies in the same industry, then in the same sector.
- NOVO-B.CO Novo Nordisk
- LLY Eli Lilly and Company
- JNJ Johnson & Johnson
- ABBV AbbVie Inc.
- MRK Merck & Co., Inc.
- UNH UnitedHealth Group Incorporated
- NVSEF Novartis AG
- AZN AstraZeneca (ADR)
Every healthcare company we cover is on the Healthcare hub.
Common questions
Is Revvity (RVTY) undervalued?
Against our fair value estimate of $64.34, RVTY at $152.89 is 58% above fair value. That is one model's answer, not a recommendation. It is built from normalized earning power with growth capped deliberately low, which understates companies whose value is mostly future growth.
Which funds own RVTY?
10 of the institutions we track reported a position in RVTY in their most recent SEC 13F filing. A 13F is filed up to 45 days after quarter end, so it tells you what a fund held then, not what it holds now.
What is RVTY's P/E ratio?
RVTY trades at 54.0 times earnings. A low P/E is not automatically cheap: on a cyclical company it is usually a warning that earnings are at a peak.
Does Revvity (RVTY) pay a dividend?
Yes. Revvity yields 0.25% at the current share price. It has paid $0.070 per share over the trailing twelve months. It has paid a dividend in each of the last 43 complete calendar years. A dividend is declared by the board and can be cut at any time; a yield is a fact about the current price, not a promise.
Where does SteadyShares get its RVTY data?
Fundamentals for RVTY come from company filings and exchange data, as listed on NYSE; institutional ownership comes from SEC 13F filings. The share price shown was last refreshed on 1 Oct 2026, 00:50 UTC and is delayed. Metrics we do not hold are left out of the page rather than estimated.
The full research page for RVTY, with financial statements, ownership detail, peer comparison and alerts, is free inside the app.
Data from company filings, exchange quotes and SEC EDGAR 13F disclosures. Quotes are delayed. Metrics we do not have are left out rather than estimated. Educational information, not financial advice.